Kalaris Therapeutics, Inc.

Developing next-gen, long-acting anti-VEGF therapies for prevalent retinal diseases.

KLRS | NDAQ

Overview

Corporate Details

ISIN(s):: US0198181036
LEI:
Country:: United States of America
Address:: 628 MIDDLEFIELD ROAD, 94301 PALO ALTO
Website:: https://kalaristx.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Kalaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing treatments for prevalent retinal diseases. The company's lead product candidate is TH103, a fully humanized, recombinant fusion protein designed as a next-generation anti-VEGF agent for intravitreal delivery. Co-developed by Dr. Napoleone Ferrara, known for his work on Avastin and Lucentis, TH103 acts as a soluble decoy receptor. A key feature is its high affinity for heparan sulfate proteoglycans (HSPG), which may act as a molecular anchor to extend its intraocular retention. This mechanism aims to reduce the frequency of injections for patients with neovascular retinal diseases, such as age-related macular degeneration.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Kalaris Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Kalaris Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Kalaris Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
DR REDDYS LABORATORIES LTD Global pharma firm providing affordable generics, APIs, and medicines to patients worldwide.	United States of America	RDY
DuChemBio Co, LTD Develops & commercializes PET/CT tracers for diagnosing cancer & neurological disorders.	South Korea	176750
Dx & Vx Co., Ltd. Develops innovative diagnostics & vaccines and provides comprehensive life science contract services.	South Korea	180400
DYNAVAX TECHNOLOGIES CORP Biopharma firm developing novel vaccines, like its adult hepatitis B vaccine, with adjuvant tech.	United States of America	DVAX
Dyne Therapeutics, Inc. Developing targeted therapies for genetic neuromuscular diseases via its FORCE™ platform.	United States of America	DYN
Eagle Veterinary Technology Co.,Ltd Manufactures vet pharma for livestock/aquaculture & distributes premium pet food.	South Korea	044960
ECO ANIMAL HEALTH GROUP PLC Develops pharmaceuticals for respiratory & enteric diseases in global swine and poultry markets.	United Kingdom	EAH
Ectin Research AB Clinical-stage biotech developing novel cancer treatments, focusing on metastatic bladder cancer.	Sweden	ECTIN B
Edesa Biotech, Inc. Develops treatments for inflammatory and immune diseases like Acute Respiratory Distress Syndrome.	United States of America	EDSA
Edgewise Therapeutics, Inc. Developing novel therapeutics for rare and serious muscle disorders.	United States of America	EWTX